Form 4: BioXcel Therapeutics Executive Matthew T. Wiley Reports Stock Transactions
SEC Form 4 Filing
Chief Commercial Officer Matthew T. Wiley of BioXcel Therapeutics, Inc. reports the vesting and sale of common stock and restricted stock units.
Summary
- Matthew T. Wiley, Chief Commercial Officer of BioXcel Therapeutics, reported transactions involving the company's common stock and Restricted Stock Units (RSUs).
- On June 15, 2024, 750 RSUs vested and were converted into common stock.
- On June 17, 2024, Wiley sold 244 shares of common stock at a price of $1.2627 per share.
- Following these transactions, Wiley directly owns 3,498 shares of common stock and 8,250 RSUs.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports stock transactions by an executive, which is a routine regulatory filing.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which is a common practice for publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the small volume of shares sold.
Key Dates
| Date | Description |
|---|---|
| March 15, 2023 | Reporting Person was granted 12,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. |
| December 14, 2023 | The Reporting Person adopted a Rule 10b5-1 trading plan. |
| June 15, 2024 | 750 Restricted Stock Units vested. |
| June 17, 2024 | 244 shares of common stock were sold at $1.2627 per share. |
| June 18, 2024 | Date of Form 4 filing. |
Keywords
BioXcel Therapeutics, BTAI, Matthew T. Wiley, Chief Commercial Officer, Form 4, Stock Transactions, Restricted Stock Units, RSUs, Common Stock, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.